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Abstract
Purpose Pemetrexed is a widely used cytostatic agent with an established exposure–response relationship. Although dos-
ing is based on body surface area (BSA), large interindividual variability in pemetrexed plasma concentrations is observed. 
Therapeutic drug monitoring (TDM) can be a feasible strategy to reduce variability in specific cases leading to potentially 
optimized pemetrexed treatment. The aim of this study was to develop a limited sampling schedule (LSS) for the assessment 
of pemetrexed pharmacokinetics.
Methods Based on two real-life datasets, several limited sampling designs were evaluated on predicting clearance, using 
NONMEM, based on mean prediction error (MPE %) and normalized root mean squared error (NRMSE %). The predefined 
criteria for an acceptable LSS were: a maximum of four sampling time points within 8 h with an MPE and NRMSE ≤ 20%.
Results For an accurate estimation of clearance, only four samples in a convenient window of 8 h were required for accurate 
and precise prediction (MPE and NRMSE of 3.6% and 5.7% for dataset 1 and of 15.5% and 16.5% for dataset 2). A single 
sample at t = 24 h performed also within the criteria with MPE and NRMSE of 5.8% and 8.7% for dataset 1 and of 11.5% 
and 16.4% for dataset 2. Bias increased when patients had lower creatinine clearance.
Conclusions We presented two limited sampling designs for estimation of pemetrexed pharmacokinetics. Either one can be 
used based on preference and feasibility.
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Introduction
Pemetrexed is an anti-folate drug which is widely used as 
first and second-line treatment of non-small cell lung cancer 
and mesothelioma [1, 2]. There is a relationship between 
pemetrexed pharmacokinetics and toxicity [3–5]. Despite 
the introduction of prophylactic use of folic acid and vitamin 
B12 to reduce the risk of haematological toxicity, neutrope-
nia remains a main exposure-related and treatment-limiting 
adverse reaction [3]. Latz et al. [3] showed that higher expo-
sure relates to both decrease in neutrophil count and a longer 
recovery time after neutropenia.
Currently, pemetrexed is dosed based on body surface 
area (BSA) and this introduces large intraindividual vari-
ability in exposure [6]. There are several other factors which 
can contribute to variability in exposure, such as change in 
renal function or drug interactions [6-9]. Since pemetrexed 
exposure correlates well with toxicity [3, 10], pharmacoki-
netically (PK) guided dosing may be a feasible strategy to 
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optimize treatment. Previously, the proposed target for safe 
and effective treatment is an AUC of 164 mg*h/L ± 25% [3, 
6]. A prerequisite to validate this target for PK-guided dos-
ing is the availability of an accurate, precise and clinically 
feasible limited sampling schedule (LSS) to assess the AUC.
From a patient’s perspective, a minimally invasive strat-
egy is desired in a short time window. Therefore, our aim 
was to develop a LSS for the assessment of pemetrexed phar-
macokinetics to use in clinical practice.
Methods
Limited sampling design evaluation
The predictive performance of several limited sampling 
designs to predict the pemetrexed clearance were evaluated. 
To assess individual exposure, the AUC can be calculated 
from clearance and the administered dose ( AUC = Dose
Clearance
 ). 
The previously developed and validated pharmacokinetic 
model by Latz et al. [3] was used to obtain the empirical 
Bayesian estimates for clearance using the post-hoc option 
in the software package NONMEM v7.4.3 [Icon, Ireland]. 
First, the full pharmacokinetic curves were fitted and 
obtained clearances were assumed to be ‘true values’. Sub-
sequently, individual clearances were estimated from sev-
eral limited sampling strategies based on the original dataset 
with certain timepoints removed.
The predictive performance was assessed with the mean 
relative prediction error (MPE %) for precision and normal-
ized root mean squared error (NRMSE %) for accuracy, 
respectively. For MPE, confidence intervals were calculated 
as described by Sheiner et al. [11]. For NRMSE, relative 
uncertainty was determined according to the distribution-
free approach of Faber [12]. Subsequently, corresponding 
confidence intervals were calculated.
Taking both patient’s perspective and statistical consid-
erations into account, the pragmatical criteria for an accept-
able LSS were defined as: a maximum of four sampling time 
points within 8 h with an MPE and NRMSE ≤ 20%. The 
value of acceptable precision, and, therefore, bias of clear-
ance, depends on multiple factors such as expected analytical 
error, therapeutic range of the drug and the purpose of the 
LSS. For pemetrexed, we found this performance acceptable 
for the estimation of pemetrexed clearance.
Datasets
Two separate datasets were used to evaluate several sam-
pling designs. The first set contained pharmacokinetic 
data of 15 pemetrexed patients (from Visser et al. 2019) 
with adequate renal function (range creatinine clearance 
according to Cockcroft–Gault (CrCl–CG) 60–166  ml/
min) [5]. Patients were treated according to label with 
a pemetrexed dose of 500 mg/m2 over a 10 min intrave-
nous infusion. For dataset 1, the following sampling times 
were available 0.17–0.5–1–2–4–8–24 h after the start of 
administration. The second set included rich pharmacoki-
netic data of 47 individuals from JMAW phase I trial of 
Eli Lilly, with varying renal function (range CrCl–CG 
17–200  ml/min.). These data were obtained through 
www.clini calst udyda tareq uest.com [13]. The dose var-
ied between patients but was administered over a 10 min 
intravenous infusion. The sampling times were 0.17–0.
25–0.5–1–2–4–6–8–12–24–48–72  h after the start of 
administration. Since the used model of Latz et al. [3] was 
designed based on sampling up to 36 h after administration 
of pemetrexed, datapoints after 36 h were excluded from 
the analysis.
Results
Table 1 presents the relevant baseline characteristics of the 
patients that were included in the two datasets and the results 
of the two best performing limited sampling designs. The 
second dataset contains patients with a wider range of both 
creatinine clearance and pemetrexed dose. For both datasets, 
several designs were tested based on the available sampling 
times. For an adequate estimation of pemetrexed clearance, 
within a sampling window of 8 h, four sampling times were 
required to reach acceptable precision and accuracy (MPE 
and NRMSE < 20%) in both datasets (not all data shown). As 
can be seen in Table 1, sampling at 0.5–2–4–8 h after admin-
istration resulted in an MPE and NRMSE of 3.6% and 5.7% 
for dataset 1. Using the second dataset, the performance of 
this sampling strategy was slightly lower but still within the 
acceptable range, with and MPE and NRMSE 15.5% and 
16.5%, respectively. Table 1 also shows the performance of 
a single sample at t = 24 h. This strategy performed more or 
less equal to multiple sampling within 8 h, with imprecision 
and inaccuracy in the same order of magnitude. For all sam-
pling designs, the MPE confidence interval did not include 
zero in both datasets, indicating a structural bias.
Figure 1a–d show true versus predicted pemetrexed 
clearance for the two proposed limited sampling designs. 
There is an acceptable correlation between the predicted 
and true clearances. Single sampling at t = 24 h for dataset 
1 (see panel C) apparently introduces a slight overpredic-
tion of pemetrexed clearance. This is not observed in the 
second dataset. In Fig. 1e–h, creatinine clearances versus 
bias (MPE %) are visualized. Generally, for lower creati-
nine clearances in dataset 2, a larger prediction error (MPE 
%) was observed.
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Discussion
Our aim was to develop a patient-friendly limited sampling 
strategy for pemetrexed to assess the exposure in clini-
cal practice and for research purposes. We found that two 
approaches resulted in the acceptable estimation of clearance 
(which serves as a proxy for the exposure). We propose two 
possible sampling schedules: the first consists of four sam-
pling times at 0.5–2–4–8 h after pemetrexed administration. 
The second approach is a single sample at t = 24 h. These 
sampling schedules can be used for dose optimization and 
therapeutic drug monitoring, in specific cases as proposed 
earlier. Either one can be chosen based on preference and 
practical feasibility.
In general, the selected LSSs seemed to slightly overpre-
dict clearance in both datasets and both sampling strategies. 
Overprediction of clearance could possibly result in unwar-
ranted dose adjustments resulting in toxic exposure. How-
ever, taking the proposed target AUC of 164 mg*h/L ± 25% 
in mind, this structural overprediction is not considered rel-
evant, because it is still well within the therapeutic range. 
Especially for dataset 2, bias increased with decreasing 
creatinine clearance. An explanation for the observation 
of increasing bias is that the used model of Latz et al. [3] 
was developed using patients with adequate renal function. 
In renal impairment, larger variability may be introduced, 
which is not observed in patients with adequate renal func-
tion. Also, with decreasing clearance, early datapoints in the 
pharmacokinetic curve become less informative. For dataset 
2, removing the 8 h timepoint resulted in unacceptable loss 
of accuracy and precision. Additionally, the result of the 
t = 24 strategy in dataset 2 showed that at a later sampling 
time there may be less bias in patients with extremely low 
creatinine clearance. Altogether, a single sample at t = 24 
may a feasible strategy for clinical practice, but it may 
require an extra hospital visit for the patient instead of a 
short prolongation of stay.
Our limited samplings strategy aimed to accurately pre-
dict pemetrexed AUC. Although Latz et al. have previously 
suggested that pharmacokinetically-guided dosing using the 
AUC may result in improved treatment [3], there is currently 
no conclusive evidence that the AUC is the best pharmacoki-
netic parameter to predict efficacy and toxicity. For example, 
the cytotoxicity of other drugs from the antifolate class, like 
methotrexate, is concentration threshold driven [14]. Pro-
spective studies should confirm the utility of AUC-guided 
dosing before implementing this in clinical practice.
Altogether, we presented two patient-friendly and reliable 
limited sampling designs for estimation of pemetrexed phar-
macokinetics. We are now using the 4-point LSS for devel-
opment of personalized dosing strategies for pemetrexed in 
ongoing clinical studies [15–17].
Table 1  Baseline characteristics 
and predictive performance 
of best performing limited 
sampling designs
Dataset 1 Dataset 2
Total N=15 N=48 
Sex
Male
Female
12
3
36
12
Age [yrs]
Median [range]
68 [43 – 77] 62 [25 – 79] 
Weight [kg]
Median [range]
72.9 [53.8 – 104.4] 79.3 [48.1 – 124.3] 
BSA [m2]
Median [range]
1.91 [1.54 – 2.22] 1.95 [1.44 – 2.47] 
Creanine clearance [ml/min]
Median [range]
112.8 [60.5 – 166.5] 72.0 [16.7 – 201.2]
Pemetrexed dose [mg/m2]
Mean [range]
400 [463 – 519] 500 [150 – 600]
No. of datapoints per curve 7 11
MPE [%] NRMSE [%] MPE [%] NRMSE [%]
Sampling design
0.5 – 2 – 4 – 8 hrs
24 hrs
3.6 ± 2.2
5.8 ± 5.3
5.7± 0.2
8.7± 0.3
15.5 ± 3.5
11.5 ± 3.6
16.5± 0.6
16.4± 0.6
MPE mean percentage error, NRMSE normalized root mean squared error, hrs hours
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Fig. 1  a True pemetrexed clearance versus predicted pemetrexed 
clearance for dataset 1, LSS 0.5–2–4–8 h. b True pemetrexed clear-
ance versus predicted pemetrexed clearance for dataset 2, LSS 0.5–
2–4–8  h. c True pemetrexed clearance versus predicted pemetrexed 
clearance for dataset 1, LSS 24rs. d True pemetrexed clearance ver-
sus predicted pemetrexed clearance for dataset 2, LSS 24  h. e Cre-
atinine clearance versus relative prediction error for dataset 1, LSS 
0.5–2–4–8  h. f Creatinine clearance versus relative prediction error 
for dataset 2, LSS 0.5–2–4–8 h. g Creatinine clearance versus relative 
prediction error for dataset 1, LSS 24 h. h Creatinine clearance versus 
relative prediction error for dataset 2, LSS 24 h
◂
